AHAli Hassanzadeh

Ali Hassanzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ali Hassanzadeh has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Roles of Laboratory Animal Models in Zoonotic Diseases: A Review on Pathogenesis, Transmission, and Prevention Strategies

    by Seyed Mohsen Mousavi Fard, Ali Sarani, Mohammad Manian, Ali Hassanzadeh Teroujeni

    Emerging zoonotic diseases have become an increasing concern for global health due to the rising incidence of pathogen transmission from animals to humans. The present study aimed to comprehensively synthesize the current knowledge on zoonotic disease outbreaks and transmission, with a specific focus on evaluating the role, applications, advantages, and limitations of laboratory animal models in this field. A peer-reviewed literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for studies published between 2000 and 2026, supplemented by earlier pivotal studies. The current study evaluated a range of models, including conventional, humanized, and transgenic mice, hamsters, ferrets, guinea pigs, rabbits, non-human primates, and emerging alternatives, focusing on their utility, strengths, and drawbacks for studying host-pathogen interactions, immune responses, tissue tropism, and disease progression. The present study underscored the importance of animal models in the preclinical assessment of antiviral agents, vaccines, monoclonal antibodies, and innovative therapeutic strategies. Recent outbreaks caused by pathogens such as SARS-CoV-2, Nipah virus, H5N1 influenza virus, Mpox virus, Ebola virus, Marburg virus, hantavirus, and Crimean-Congo hemorrhagic fever virus have highlighted the urgent necessity to enhance comprehension of zoonotic disease emergence and transmission. The current challenges included species-specific differences, translational limitations, reproducibility, and ethical considerations, as well as emerging alternatives such as organoids, organ-on-chip platforms, and computational modeling, all of which were addressed in the present findings. Integrating advanced animal models with One Health approaches can strengthen disease surveillance and accelerate therapeutic development.

  • Open Access

    Comparison of machine learning models with conventional statistical methods for prediction of percutaneous coronary intervention outcomes: a systematic review and meta-analysis

    by Sepehr Nayebirad, Ali Hassanzadeh, Amir Mohammad Vahdani, Aida Mohamadi, Shayan Forghani, Akbar Shafiee, Farzad Masoudkabir

    Percutaneous coronary intervention (PCI) has been the main treatment of coronary artery disease (CAD). In this review, we aimed to compare the performance of machine learning (ML) vs. logistic regression (LR) models in predicting different outcomes after PCI. Studies using ML or deep learning (DL) models to predict mortality, MACE, in-hospital bleeding, and acute kidney injury (AKI) after PCI or primary PCI were included. Articles were excluded if they did not provide a c-statistic, solely used ML models for feature selection, were not in English, or only used logistic or LASSO regression models. Best-performing ML and LR-based models (LR model or conventional risk score) from the same studies were pooled separately to directly compare the performance of ML versus LR. Risk of bias was assessed using the PROBAST and CHARMS checklists. A total of 59 studies were included. Meta-analysis showed that ML models resulted in a higher c-statistic compared to LR in long-term mortality (0.84 vs. 0.79, P-value = 0.178), short-term mortality (0.91 vs. 0.85, P = 0.149), bleeding (0.81 vs. 0.77 P = 0.261), acute kidney injury (AKI; 0.81 vs. 0.75, P = 0.373), and major adverse cardiac events (MACE; 0.85 vs. 0.75, P = 0.406). PROBAST analysis showed that 93% of long-term mortality, 70% of short-term mortality, 89% of bleeding, 69% of AKI, and 86% of MACE studies had a high risk of bias. No statistical significance existed between ML and LR model. In addition, the high risk of bias in ML studies and complexity in interpretation undermines their validity and may impact their adaption in a clinical settings.


  • Implementing novel complete blood count-derived inflammatory indices in the diabetic kidney diseases diagnostic models

    by Ali Hassanzadeh, Mehdi Allahdadi, Sepehr Nayebirad, Nazli Namazi, Ensieh Nasli-Esfahani

    Objectives Hemogram inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), red-cell distribution width (RDW), and mean platelet volume (MPV) have been associated with type 2 diabetes mellitus (T2DM) and its complications, namely diabetic kidney diseases (DKD). We aimed to develop and validate logistic regression (LR) and CatBoost diagnostic models and study the role of adding these markers to the models. Methods All individuals who were managed in our secondary care center from March 2020 to December 2023 were identified. After excluding the ineligible patients, train-test splitting, and data preprocessing, two baseline LR and CatBoost-based models were developed using demographic, clinical, and laboratory features. The AUC-ROC of the models with biomarkers (NLR, PLR, RDW, and MPV) was compared to the baseline models. We calculated net reclassification improvement (NRI) and integrated discrimination index (IDI). Results One thousand and eleven T2DM patients were eligible. The AUC-ROC of both LR (0.738) and CatBoost (0.715) models was comparable. Adding target inflammatory markers did not significantly change the AUC-ROC in both LR and CatBoost models. Adding RDW to the baseline LR model reclassified 41.7% of patients without DKD, in the cost of misclassification of 38.4% of DKD cases. This change was absent in CatBoost models, and other markers did not achieve improved NRI or IDI. Conclusion The basic models with demographical and clinical features had acceptable performance. Adding RDW to the basic LR model improved the reclassification of the non-DKD participants. However, adding other hematological indices did not significantly improve the LR and CatBoost models’ performance.


  • Open Access

    Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs)

    by Ali Hassanzadeh, Navid Shomali, Amin Kamrani, Mohammad Sadegh Soltani-Zangbar, Hadi Nasiri, Morteza Akbari

    A major characteristic of cancer is dysregulated cell division, which results in aberrant growth of cells. Consequently, medicinal targets that prevent cell division would be useful in the fight against cancer. The primary regulator of proliferation is a complex consisting of cyclin and cyclin-dependent kinases (CDKs). The FDA has granted approval for CDK inhibitors (CDKIs) to treat metastatic hormone receptor-positive breast cancer. Specifically, CDK4/6 CDKIs block the enzyme activity of CDK4 and CDK6. Unfortunately, the majority of first-generation CDK inhibitors, also known as pan-CDK inhibitors because they target multiple CDKs, have not been authorized for clinical use owing to their serious side effects and lack of selection. In contrast to this, significant advancements have been created to permit the use of pan-CDK inhibitors in therapeutic settings. Notably, the toxicity and negative consequences of pan-CDK inhibitors have been lessened in recent years thanks to the emergence of combination therapy tactics. Therefore, pan-CDK inhibitors have renewed promise for clinical use when used in a combination regimen. The members of the CDK family have been reviewed and their primary roles in cell cycle regulation were covered in this review. Next, we provided an overview of the state of studies on CDK inhibitors.


  • Open Access

    Disseminated mycobacterium genavense infection with central nervous system involvement in an HIV patient: a case report and literature review

    by Ali Hassanzadeh, Malihe Hasannezhad, Ladan Abbasian, Sara Ghaderkhani, Fereshteh Ameli, Mehdi Allahdadi

    Background: Immunodeficient patients, particularly HIV patients, are at risk of opportunistic infections. Nontuberculous mycobacteria can cause severe complications in immunodeficient patients. Case Presentation: We describe a 57-year-old HIV patient, primarily presented with coughs and constitutional symptoms, with a unique Mycobacterium genavense abdominal, pulmonary, and central nervous system infection, accompanied by intracranial masses. Conclusion: The diagnosis of NTM, including M. genavense, must always be considered by clinicians in immunodeficient patients, especially those with HIV, who have a compromised immune system.


  • Open Access

    Predictors of major adverse cardiac and cerebrovascular events after percutaneous coronary intervention in older adults: a systematic review and meta-analysis

    by Arash Jalali, Ali Hassanzadeh, Mohammad Sadeq Najafi, Sepehr Nayebirad, Mohadese Dashtkoohi, Zahra Karimi, Akbar Shafiee

    Aim: We systematically reviewed and meta-analyzed the predictors of major adverse cardiac and cerebrovascular events (MACE/MACCE) in older adults who underwent PCI. Methods: Three databases, PubMed, Embase, and Scopus, were searched for observational studies considering the out-of-hospital MACE/MACCE in adults ≥ 60 years old with coronary artery disease (acute or chronic) who underwent PCI. Studies were eligible if they had determined at least two statistically significant predictors of MACE/MACCE by multivariable analysis. We used the QUIPS tool to evaluate the risk of bias in the studies. Random-effects meta-analysis was utilized to pool the hazard ratios (HRs) of the most reported predictors. Results: A total of 34 studies were included in the review. Older age (HR = 1.04, 95% Confidence Interval (CI): 1.03–1.06, P-value < 0.001), diabetes (HR = 1.36, 95% CI: 1.22–1.53, P < 0.001), history of myocardial infarction (MI) (HR = 1.88, 95% CI: 1.37–2.57, P < 0.001), ST-elevation MI (STEMI) at presentation (HR = 1.72, 95% CI: 1.37–2.18, P < 0.001), reduced left ventricular ejection fraction (LVEF) (HR = 2.01, 95% CI: 1.52–2.65, P < 0.001), successful PCI (HR = 0.35, 95% CI: 0.27–0.47, P < 0.001), eGFR (HR = 0.99, 95% CI: 0.97-1.00; P-value = 0.04) and left main coronary artery (LMCA) disease (HR = 2.07, 95% CI: 1.52–2.84, P < 0.001) were identified as predictors of MACE. Conclusion: We identified older age, diabetes, history of MI, STEMI presentation, lower LVEF, and LMCA disease increased the risk of MACE/MACCE after PCI in older adults. Meanwhile, higher eGFR and successful PCI predicted lower adverse events risk. Future studies should focus on a more robust methodology and a precise definition of MACE. Registration: PROSPERO (CRD42023480332).


  • Open Access

    Detailed role of mesenchymal stem cell (MSC)-derived exosome therapy in cardiac diseases

    by Ali Hassanzadeh, Navid Shomali, Amin Kamrani, Hadi Nasiri, Javad Ahmadian Heris, Maryam Pashaiasl, Mohammadreza Sadeghi, Shahram Sadeghvand, Zahra Valedkarimi, Morteza Akbari

    Coronary heart disease (CHD) continues to be the leading cause of morbidity and mortality. There are numerous therapeutic reperfusion methods, including thrombolytic therapy, primary percutaneous coronary intervention, and anti-remodeling drugs like angiotensin-converting enzyme inhibitors and beta-blockers. Despite this, there is no pharmacological treatment that can effectively stop cardiomyocyte death brought on by myocardial ischemia/reperfusion (I/R) injury. For the purpose of regenerating cardiac tissue, mesenchymal stem cell (MSC) therapy has recently gained more attention. The pleiotropic effects of MSCs are instead arbitrated by the secretion of soluble paracrine factors and are unrelated to their capacity for differentiation. One of these paracrine mediators is the extracellular vesicle known as an exosome. Exosomes deliver useful cargo to recipient cells from MSCs, including peptides, proteins, cytokines, lipids, miRNA, and mRNA molecules. Exosomes take part in intercellular communication processes and help tissues and organs that have been injured or are ill heal. Exosomes alone were found to be the cause of MSCs' therapeutic effects in a variety of animal models, according to studies. Here, we have focused on the recent development in the therapeutic capabilities of exosomal MSCs in cardiac diseases.